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Abstract
Introduction Mutations in BRCA1, BRCA2, ATM, TP53, CHK2
and PTEN account for only 20–30% of the familial aggregation
of breast cancer, which suggests the involvement of additional
susceptibility genes. The ATR (ataxia-telangiectasia- and Rad3-
related) kinase is essential for the maintenance of genomic
integrity. It functions both in parallel and cooperatively with ATM,
but whereas ATM is primarily activated by DNA double-strand
breaks induced by ionizing radiation, ATR has been shown to
respond to a much broader range of DNA damage. Upon
activation, ATR phosphorylates several important tumor
suppressors, including p53, BRCA1 and CHK1. Based on its
central function in the DNA damage response, ATR  is a
plausible candidate gene for susceptibility to cancer.
Methods We screened the entire coding region of the ATR
gene for mutations in affected index cases from 126 Finnish
families with breast and/or ovarian cancer, 75 of which were
classified as high-risk and 51 as moderate-risk families, by using
conformation sensitive gel electrophoresis and direct
sequencing.
Results A large number of novel sequence variants were
identified, four of which – Glu254Gly, Ser1142Gly, IVS24-
48G>A and IVS26+15C>T – were absent from the tested
control individuals (n = 300). However, the segregation of these
mutations with the cancer phenotype could not be confirmed,
partly because of the lack of suitable DNA samples.
Conclusion The present study does not support a major role for
ATR mutations in hereditary susceptibility to breast and ovarian
cancer.
Introduction
Of all breast and ovarian cancers, 5–10% are due to genetic
predisposition [1]. Mutations in the two high penetrance
genes BRCA1 and BRCA2 are well known, but they account
for only 20–30% of the familial aggregation of breast cancer.
The remaining cases could be the result of a few additional, yet
unidentified, high penetrance mutations, but the polygenic
model may provide a more plausible explanation [2]. Accord-
ing to this model, genetic susceptibility to breast cancer is due
to several loci, each conferring a modest independent risk [3].
Because the protein products of the genes thus far associated
with breast and/or ovarian cancer predisposition are central
players in the pathways involved in cell cycle checkpoint func-
tions, and in the sensing, transduction and repair of DNA
lesions [4], other similarly acting genes may represent new
potential candidates.
The ATR (ataxia-telangiectasia- and Rad3-related) kinase is
essential for the maintenance of genomic integrity. It is a key
activator of the cellular responses to DNA lesions [5]. In
response to DNA double-strand breaks induced by ionizing
radiation ATR, along with ATR-interacting protein, acts in par-
allel with ATM (ataxia-telangiectasia mutated), which is defec-
tive in the neurodegenerative disorder ataxia-telangiectasia
and is also associated with breast cancer susceptibility [6-9].
Whereas ATM is responsible for the immediate and rapid
response to double-strand breaks, ATR joins in later and main-
tains the phosphorylated state of specific substrates. How-
ever, this is not the main role played by ATR; it also responds
to ultraviolet-induced lesions, stalled replication forks and
hypoxia [5]. In response to these events, ATR phosphorylates
key proteins in various branches of the DNA damage response
pathways, such as p53, BRCA1, CHK1 and Rad17, thereby
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activating DNA repair, cell cycle checkpoints, or apoptosis
[10,11].
The cellular functions of ATR are indispensable, as demon-
strated in mice, in which biallelic disruption of ATR leads to
early embryonic lethality. In contrast, ATR+/- mice exhibit only a
small decrease in survival but tumor incidence is increased
[12]. In humans a connection between ATR defects and tum-
origenesis has also been suggested, mainly by studies report-
ing somatic changes in ATR  in gastric and endometrial
cancers exhibiting microsatellite instability [13,14]. Conse-
quently, it has been proposed that ATR serves as a haploinsuf-
ficient tumour suppressor on a mismatch repair deficient
background [15].
Recently, inherited defects in ATR signalling were shown to
associate with Seckel syndrome, because patients in two fam-
ilies were found to be homozygous for a hypomorphic ATR
mutation. Seckel syndrome is a heterogenous recessive disor-
der that is characterized by dwarfism, developmental delay
and severe microcephaly. It shares an overlap in clinical fea-
tures with two recessive cancer susceptibility syndromes,
Nijmegen breakage syndrome and Fanconi anemia (FA)
[16,17]. Interestingly, the gene that is defective in two FA com-
plementation groups, namely FA-B and FA-D1, has been iden-
tified as BRCA2 – a major breast cancer susceptibility gene
[18,19]. In addition, carriers of the Nijmegen breakage syn-
drome Slavic founder mutation appear to be at increased risk
for breast cancer [20]. Thus far, predisposition to cancer has
not been reported in patients with Seckel syndrome. However,
various cell lines in which ATR has been inactivated exhibit
genetic instability, and this may predict proneness to cancer
[17].
Based on this, we wanted to determine whether ATR germline
mutations are involved in susceptibility to breast and/or ovar-
ian cancer, and conducted a mutation analysis of all 47 coding
exons and exon–intron boundaries in the affected index cases
in 126 families.
Materials and methods
Subjects
The index cases of 126 breast and/or ovarian cancer families
originating from northern Finland were screened for ATR
germline mutations. Of the studied families, 94 were affected
by breast, 29 by breast/ovarian and three by ovarian cancer.
All index cases had been diagnosed with either breast or ovar-
ian cancer. 75 of the families were classified as high-risk fam-
ilies and were defined as follows: three or more cases of
breast and/or ovarian cancer in first- or second-degree rela-
tives; or two cases of breast and/or ovarian cancer in first- or
second-degree relatives, of which at least one had early dis-
ease onset (age ≤35 years), bilateral disease, or multiple pri-
mary tumours. Most of the high-risk families contained three or
more cancer cases. The remaining 51 families contained two
cases of breast and/or ovarian cancer in first- or second-
degree relatives and were considered to be at moderate dis-
ease risk. All of the high-risk families had previously been
screened for germline mutations in BRCA1, BRCA2, CHK2
and TP53 [21-23] and 10 families were known to have dis-
ease-related mutations in BRCA1 or BRCA2. The frequencies
of all observed germline variants were assessed in either 100
or 300 control individuals, who were anonymous cancer-free
blood donors originating from the same geographical region
as the studied families.
All patients gave informed consent for acquisition of pedigree
data and blood specimens for use in a study on cancer sus-
ceptibility gene mutations. Approval to perform the study was
obtained from the Ethical Board of the Northern Ostrobothnia
Health Care District and the Finnish Ministry of Social Affairs
and Health.
Mutation analysis
DNA was extracted from blood lymphocytes using either the
standard phenol–chloroform protocol or the Puregene D-50K
purification kit (Gentra, Minneapolis, MN, USA). Screening of
the protein encoding and exon–intron boundary regions of
ATR was done by conformation sensitive gel electrophoresis
(CSGE), which is a cost-efficient way to scan for mutations
with high detection sensitivity and specificity [24,25], or by
direct sequencing. Sequencing analysis was performed using
the Li-Cor IR2 4200-S DNA Analysis system (Li-Cor Inc., Lin-
coln, NE, USA) and the SequiTherm EXCEL™II DNA Sequenc-
ing Kit-LC (Epicentre Technologies, Madison, WI, USA).
Oligonucleotides for CSGE and sequencing (Table 1) were
designed using Primer3 software [26], utilizing sequence
information obtained from public databases. Polymerase chain
reaction conditions for CSGE and sequencing are available
upon request.
Statistical analyses
Fisher's exact test or χ2 test was used to determine statistical
significance (SPSS version 12.0 for Windows; SPSS Inc.,
Chicago, IL, USA). All P values were two sided.
Results
Mutation analysis revealed several alterations in the ATR gene.
Altogether, 23 nucleotide substitutions were observed: 17 in
the exon and six in the intron regions (Tables 2 and 3). Eleven
of the exonic changes resulted in amino acid substitutions,
eight of which were novel and three were polymorphisms
reported in the single nucleotide polymorphism database [27].
The location of the amino acid changes is summarized in Fig.
1. All observed nucleotide alterations were assessed for pos-
sible effects on splicing consensus sequences [28], and the
coding sequence variants were tested using the ESEfinder
program [29] to identify those that reduced the exonic splicing
enhancer (ESE) score below the calculated threshold.Available online http://breast-cancer-research.com/content/7/4/R495
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Table 1
Primers used to amplify exons and splice junctions of ATR
Exon Forwarda Reverse
1 ccgggtcctatgcagaaaag aggggagagcacgtgaaac
2 cattgacactgaacacatttgatg tctaaaactacatggagaaaatgct
3 ggcccacagtctggtttct gtaatatttcagaagagcagtaaaagg
4a tcgtcaaggatttagcaaatga acgagtaagaaccattaataaagtgac
4b atgtgatgggtcatgctgtg gctcttcatagagtttcaattggtc
4c tccaaaaattaaatccctagcaa tctcacatagaccttcctgacttg
4d aaactctgtgtcatgtttgaagac gccagactacactatgaaaatcatta
5 cattcttgctgcctatgaataa aaatcaaagcacttaactaaagctga
6 tctaaatatgtttcatgttttaaccaa tgagtcaagtgaataatgagtaaaca
7 tggctttactacaattttatgtttgac cacttaggcttcaggcaaaa
8b tttaaaagagatatgattaaggaaaag cacacattcttgtgagcactt
9 aaatgtattttaagtgttacttgactttt aaccctgcatacatagccaga
10 gtcccaaattaagcaagactattt caaggcttcagtctaattcttttac
11 tcatggcatattatttgttgac gaacaataaaattaactggttaaagaa
12 gaggttgataatttttgtttttaacat ccatttttaacagcaagcaaa
13 tgagtcaacatgaatttatttgtagat aaagaaaagcaagcaaaataaaac
14 ctctatggtggcttaaaaagtattagt caaagtcaaaatctagaatggaatg
15 ctccaaatatgtgtggcattt accctctttcctagaagaatgttac
16 ctcctgatgtactaatagcatgttaaa tgaccaaaaatatgatttcttcaat
17 gcttttggagaaacttaattaacca tgtttgtagctagatgcagaattt
18b tgtccttagggctcatctgc tgaacccaatttccctcaaa
19 gctgccttttaatctattgtttg cattaccatcagtaattttgagacat
20 ggccttagtttcaacttttactttaca caggaattagctatcagaataggact
21 gagaattcaggcctttggaa aatgtcattttgtcatcttttcttt
22 aactcatcaaaaactagctgaaaaa ggataagctgaatagttctttgtaaat
23 ccatggaaaaagcagtacacc aaaacaaaaaggagtttcacaagt
24 gcataaataaagcgaagtgcaa ggccaaaaaaatcgcatta
25 agtcaactgaaggagttgctg ttgtgtgtgctaggcattcag
26 ttatctcacatgctactctttgaca catttcctactaataggtagcctttc
27 ttagaatggttagctttagatgtcata agaactgataaagggaagagctaa
28 caattgttctgttgttagttacattct gcatagcatataaaacattcaataaaa
29 aaacaggtggttttatagttttatttc aaggtttccagagttcctattca
30 aagggcaataaggtaaatagtaat aaattacccaattcactaactaaaaa
31 gaacaaaatacaatataatgcaaattcaa accgcacccatcctaaaact
32 ttgatatttcagctgaccattttatc ccaaactcactatcaattatttactcaaa
33 caactgtgtattttaaattctttatttctg cacccccaaataatatccaa
34b attgggaacagaggctttca gacatttccctggccattac
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Of the observed amino acid substitutions, four were located in
known functional sites: Arg2008Leu and Tyr2132Asp to the
FAT (FRAP/ATM/TRRAP) domain, and Arg2425Gln and
Ile2435Val to the PI3Kc (phosphoinositide 3-kinase related
catalytic) domain. The novel Arg2008Leu, Tyr2132Asp and
Ile2435Val alterations occurred in one index case each. Inter-
estingly, Arg2008Leu appeared to have an effect on two ESEs
(SF2/ASF and SC35), as predicted by the ESEfinder
program.
Arg2008Leu was identified in a patient with both ovarian and
colon cancer at age 51 years, and her sister, diagnosed with
breast cancer at age 72 years, was found to be a carrier. How-
ever, because Arg2008Leu, Tyr2132Asp or Ile2435Val carri-
ers were also observed in control individuals, these changes
were all classified as rare variants. Arg2425Gln is a common
polymorphism described in the single nucleotide polymor-
phism database, and its frequency was similar in cases
(27.8%) and controls (24.0%).
The rest of the amino acid substitutions were all located out-
side the kinase and FAT/FATC domains, although two of
these, Glu254Gly and Ser1142Gly, were absent from the
tested controls. Glu254Gly affects a nonconserved residue,
and was seen in one patient diagnosed with breast cancer at
age 37 years. However, her maternal cousin, with bilateral
breast cancer at ages 45 and 55 years, was not a carrier. The
other change, Ser1142Gly, affects a residue that is also con-
served in ATR of Xenopus laevis and in mei41 of Drosophila
melanogaster [30]. Ser1142Gly was seen in two index cases
with breast cancer (2/126; P = 0.09). In the first family the
patient was diagnosed at age 64 years. Two of her daughters
had breast cancer at ages 49 and 40 years, but both tested
negative for Ser1142Gly. Also, two sisters of the index had
breast cancer at unknown ages, but no samples were available
for mutation testing. In the second family the index patient was
diagnosed at age 59 years, but her sister, who had breast can-
cer at age 45 years, was not a carrier. Neither Glu254Gly nor
Ser1142Gly had an affect on splicing consensus sequences
or ESEs.
Of the six intronic changes, two were absent from the tested
control individuals: IVS24-48G>A was observed in the index
case of three families (3/126; P = 0.03) and IVS26+15C>T
was observed in one case. Unfortunately, only one additional
DNA sample from an affected relative was available for muta-
tion testing, and this maternal cousin of the index case proved
negative for IVS24-48G>A. Also IVS31-74G>A was found
more frequently in cases (8.7%) than in control individuals
(4.3%), but the difference was only marginally significant
(odds ratio 2.1, 95% confidence interval 0.92–4.85; P  =
0.07). None of the observed intron changes had an affect on
consensus splice sites.
Discussion
ATR plays a critical role in the maintenance of genomic integ-
rity. A number of tumour suppressor proteins act downstream
of ATR, placing it high in the DNA damage response cascade
[5]. Impaired ATR signalling has been shown to result in
Seckel syndrome, but thus far predisposition to cancer in
these patients has not been reported [16]. Nevertheless, cell
lines with inactivated ATR exhibit genetic instability, which may
suggest proneness to cancer [17].
To investigate the possible role played by ATR germline muta-
tions in hereditary predisposition to breast and ovarian cancer,
36 tcacatacttttgatccctaatca acctagaatatgctaagacatgtga
37 tttttgtgaaaacggtatgtgg agactgtccagccaaatctga
38 tgtgaaatgaactgatatactgattttt cgccctggaacttgtatcta
39 aactctcatcatgaatactttttaagtt aaaaactgctttattaagacaaatcat
40 ttgtaaaagtgaaatttttgttatagtgg ttgtgaaatacactttttatcttaatttga
41 tttacacagaaatttttggcccta caactctgaaataaaagcaatctgg
42 tttggttatgaaatgaacaatcttt aggaagggatggaaacactt
43 agtagatgtttcttgtccaattttaac catatgaggccaatataaatctaaaa
44 gttgttatggttgaatgtttattttta caaggaagatacagttgttgagaa
45 tggacatgaagttctttgagtaaa caaacatatgtaggggccaat
46 agcttctcatccttcacttaaa aactatagctgcatatcaagttca
47a gggtattggtcagtaaaatggta ccacagattcataccaaatgc
47b gaaggacatgtgcattaccttatac cttgcttgtttcttgcaaatatag
aAll primer sequences are shown in the 5' to 3' direction. bThe amplified fragment was analyzed by direct sequencing.
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the whole coding region of the gene was screened for muta-
tions in the index cases from 126 families. We found a number
of novel sequence variants, but we did not identify any clearly
pathogenic alterations. Only two of the observed missense
changes, Glu254Gly and Ser1142Gly, were absent from con-
trol individuals. However, because the variants did not segre-
gate with the cancer phenotype in these families, they are
unlikely to be important cancer susceptibility alleles. Evalua-
tion of the intronic variants IVS24-48G>A and IVS26+15C>T
is more difficult because only one additional DNA sample was
available for mutation testing, but neither had any affect on
consensus splicing sequences. The possible association of
Table 2
Observed sequence variation in the protein-encoding regions of ATR
Exon Nucleotide change Effect on protein Carrier frequency P Statusa
Familial cases Controls
3 268C>T His90Tyr 12.7% (16/126) 10.3% (31/300) 0.50 Novel
4 632T>C Met211Thr 54.0% (68/126) 47.3% (142/300) 0.20 Reported
761A>G Glu254Gly 0.8% (1/126) - (0/300) 0.30 Novel
891G>C Lys297Asn 1.6% (2/126) 2.3% (7/300) 1.00 Reported
8 1776T>A Gly592Gly 50.8% (64/126) 41.0% (41/100) 0.18 Reported
1815T>C Asp605Asp 46.8% (59/126) 49.0% (49/100) 0.79 Reported
14 2946C>T Phe982Phe 0.8% (1/126) 2.0% (6/300) 0.68 Novel
17 3424A>G Ser1142Gly 1.6% (2/126) - (0/300) 0.09 Novel
21 3893A>T Asp1297Val 0.8% (1/126) 1.0% (3/300) 1.00 Novel
26 4576A>G Ile1526Val 4.0% (5/126) 2.0% (6/300) 0.31 Novel
30 5208T>C Tyr1736Tyr 23.8% (30/126) 37.0% (37/100) 0.03 Reported
32 5459T>C Tyr1820Tyr 26.2% (33/126) 31.0% (31/100) 0.43 Reported
35 6023G>T Arg2008Leu 0.8% (1/ 126) 0.3% (1/300) 0.51 Novel
38 6394T>G Tyr2132Asp 0.8% (1/126) 0.3% (1/300) 0.51 Novel
43 7274G>A Arg2425Gln 27.8% (35/126) 24.0% (72/300) 0.46 Reported
7303A>G Ile2435Val 0.8% (1/126) 0.3% (1/300) 0.51 Novel
47 7875A>G Gln2625Gln 27.0% (34/126) 35.0% (35/100) 0.19 Reported
aNovel or reported in the National Center for Biotechnology Information single nucleotide polymorphism database http://www.ncbi.nlm.nih.gov/
SNP/.
Table 3
Observed sequence variation in the intron regions of ATR
Location Nucleotide change Carrier frequency P Statusa
Familial cases Controls
IVS2-51 A>T 9.5% (12/126) 9.0% (9/100) 0.89 Novel
IVS16-26 T>A 2.4% (3/126) 4.3% (13/300) 0.41 Novel
IVS18-22 G>C 4.8 % (6/126) 4.0% (12/300) 0.72 Novel
IVS24-48 G>A 2.4% (3/126) - (0/300) 0.03 Novel
IVS26+15 C>T 0.8% (1 /126) - (0/300) 0.30 Novel
IVS31-74 G>A 8.7% (11/126) 4.3% (13/300) 0.07 Novel
aNovel or reported in the National Center for Biotechnology Information single nucleotide polymorphism database http://www.ncbi.nlm.nih.gov/
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the identified rare variants with predisposition to cancer must
be demonstrated by more extensive case–control studies.
The performed mutation analysis is to our knowledge the first
to investigate the possible association of germline ATR muta-
tions with cancer predisposition. However, the results of the
study suggest that ATR is not involved in hereditary suscepti-
bility to breast and ovarian cancer. The lack of deleterious
germline mutations could reflect a fundamental role for ATR in
cell viability, including DNA replication [5]. Nonetheless,
because ATR changes have thus far been reported only in
gastric and endometrial tumours exhibiting microsatellite insta-
bility, it is also possible that breast and/or ovarian cancer is not
the primary cancer phenotype associated with germline muta-
tions in this gene [13,14]. These findings need confirmation by
other studies.
Conclusion
Based on its central role in the maintenance of genomic integ-
rity, we hypothesized that germline mutations in ATR  may
account for some breast and/or ovarian cancer families. How-
ever, analysis of 126 index cases suggests that ATR mutations
do not play a major role in hereditary susceptibility to these
cancers.
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